<DOC>
	<DOCNO>NCT00705198</DOCNO>
	<brief_summary>The purpose study confirm safety efficacy temozolomide patient newly diagnose malignant glioma ( concomitant radiotherapy monotherapy ) relapse malignant glioma ( monotherapy ) use daily medical practice . Post-marketing survey consider applicable clinical trial thus result survey post conclusion . The result submit public health official require applicable national international law .</brief_summary>
	<brief_title>Temozolomide All-Case-Registered Surveillance ( Designated Drug Use Investigation ) ( Study P05062 )</brief_title>
	<detailed_description>Patients invite participate study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>All patient treat temozolomide newly diagnose malignant glioma ( concomitant radiotherapy monotherapy ) relapse malignant glioma ( monotherapy ) . Patients history hypersensitivity temozolomide dacarbazine . Pregnant woman woman may pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>